Publications by authors named "Soaira Mendoza"
The frequency of obesity, insulin resistance, type 2 diabetes mellitus and other components of metabolic syndrome appear to be significantly elevated in some psychiatric patients. This is a notable example of genetic/environment interaction. Considering the genetic contribution, evidence of insulin resistance in persons with schizophrenia was reported in the pre-pharmacological era.
View Article and Find Full Text PDFArticle Synopsis
- The study examined how olanzapine affects insulin counter-regulatory factors, fibrinogen, and C-reactive protein levels in patients with chronic schizophrenia, along with the impact of metformin on these factors.
- 37 patients were given olanzapine for 14 weeks, with 19 receiving metformin and 18 receiving a placebo in a randomized trial.
- Results showed decreased levels of cortisol, tumor necrosis factor-alpha, and fibrinogen in both groups, with metformin showing a potential beneficial effect despite not preventing weight gain associated with olanzapine.
Objective: To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine.
Method: Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n = 20; 850 to 1700 mg daily) or placebo (n = 20) group in a 14-week double-blind study. Waist circumference (WC), BWG, body mass index (BMI) fasting glucose, insulin, and lipids were evaluated at baseline and at Weeks 7 and 14 of treatment.